Listed

West Pharmaceutical Services Inc

WSTNYSECIK 105770HealthcareFiscal year ends Dec 31

Latest reported revenue, Q3 FY2026$874.5mRevenue, Q3 FY2026, three months to 2026-09-30$874.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0000105770-26-000121.Report this figureThree months to Sep 30, 2026, from the 10-Q filed Oct 29, 2026.

Latest quarter: Q3 FY2026

Three months to Sep 30, 2026, against the same quarter a year earlier.

  • Revenue$874.5mRevenue, Q3 FY2026, three months to 2026-09-30$874.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0000105770-26-000121.Report this figure+8.7% on a year earlier
  • Gross margin39.7%Gross margin, Q3 FY2026, three months to 2026-09-30. gross profit / revenueGross profit: $347.4m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-10-29, accession 0000105770-26-000121.Revenue: $874.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0000105770-26-000121.Report this figure+3.1 pts on a year earlier
  • Operating margin30.6%Operating margin, Q3 FY2026, three months to 2026-09-30. operating income / revenueOperating income: $267.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-10-29, accession 0000105770-26-000121.Revenue: $874.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0000105770-26-000121.Report this figure+9.7 pts on a year earlier
  • Net margin24.5%Net margin, Q3 FY2026, three months to 2026-09-30. net income / revenueNet income: $214.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-29, accession 0000105770-26-000121.Revenue: $874.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0000105770-26-000121.Report this figure+7.1 pts on a year earlier
  • Diluted EPS$3.02Diluted EPS, Q3 FY2026, three months to 2026-09-30$3.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-10-29, accession 0000105770-26-000121.Report this figure+57.3% on a year earlier
  • Free cash flow$150.4mFree cash flow, Q3 FY2026, three months to 2026-09-30. operating cash flow − capital expenditureOperating cash flow: $189.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-10-29, accession 0000105770-26-000121. Derived: 9-month figure less the 6-month figure.Capital expenditure: $39.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-10-29, accession 0000105770-26-000121. Derived: 9-month figure less the 6-month figure.Report this figure+12.3% on a year earlier

Last eight quarters

Full statements
Revenue$874.5mGross margin 39.7%
Diluted EPS$3.02, Q3 FY2026
Free cash flow$150.4m, Q3 FY2026
West Pharmaceutical Services Inc, key figures for the last eight quarters
Line itemUnitQ4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Q3 FY20262026-09-30Shape over the periods
Revenue$m749Revenue, Q4 FY2024, three months to 2024-12-31$748.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000105770-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure698Revenue, Q1 FY2025, three months to 2025-03-31$698.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-23, accession 0000105770-26-000049.Report this figure767Revenue, Q2 FY2025, three months to 2025-06-30$766.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-23, accession 0000105770-26-000099.Report this figure805Revenue, Q3 FY2025, three months to 2025-09-30$804.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0000105770-26-000121.Report this figure805Revenue, Q4 FY2025, three months to 2025-12-31$805.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000105770-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure845Revenue, Q1 FY2026, three months to 2026-03-31$844.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-23, accession 0000105770-26-000049.Report this figure872Revenue, Q2 FY2026, three months to 2026-06-30$872.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-23, accession 0000105770-26-000099.Report this figure875Revenue, Q3 FY2026, three months to 2026-09-30$874.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0000105770-26-000121.Report this figure
Gross margin%36.5%Gross margin, Q4 FY2024, three months to 2024-12-31. gross profit / revenueGross profit: $273.6m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-17, accession 0000105770-26-000010. Derived: 12-month figure less the 9-month figure.Revenue: $748.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000105770-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure33.2%Gross margin, Q1 FY2025, three months to 2025-03-31. gross profit / revenueGross profit: $231.9m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-04-23, accession 0000105770-26-000049.Revenue: $698.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-23, accession 0000105770-26-000049.Report this figure35.7%Gross margin, Q2 FY2025, three months to 2025-06-30. gross profit / revenueGross profit: $273.9m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-07-23, accession 0000105770-26-000099.Revenue: $766.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-23, accession 0000105770-26-000099.Report this figure36.6%Gross margin, Q3 FY2025, three months to 2025-09-30. gross profit / revenueGross profit: $294.3m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-10-29, accession 0000105770-26-000121.Revenue: $804.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0000105770-26-000121.Report this figure37.8%Gross margin, Q4 FY2025, three months to 2025-12-31. gross profit / revenueGross profit: $303.9m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-17, accession 0000105770-26-000010. Derived: 12-month figure less the 9-month figure.Revenue: $805.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000105770-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure35.1%Gross margin, Q1 FY2026, three months to 2026-03-31. gross profit / revenueGross profit: $296.4m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-04-23, accession 0000105770-26-000049.Revenue: $844.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-23, accession 0000105770-26-000049.Report this figure37.7%Gross margin, Q2 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $329.2m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-07-23, accession 0000105770-26-000099.Revenue: $872.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-23, accession 0000105770-26-000099.Report this figure39.7%Gross margin, Q3 FY2026, three months to 2026-09-30. gross profit / revenueGross profit: $347.4m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-10-29, accession 0000105770-26-000121.Revenue: $874.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0000105770-26-000121.Report this figure
Operating margin%21.3%Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: $159.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-17, accession 0000105770-26-000010. Derived: 12-month figure less the 9-month figure.Revenue: $748.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000105770-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure15.3%Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: $107.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-04-23, accession 0000105770-26-000049.Revenue: $698.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-23, accession 0000105770-26-000049.Report this figure20.1%Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: $153.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-23, accession 0000105770-26-000099.Revenue: $766.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-23, accession 0000105770-26-000099.Report this figure20.8%Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: $167.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-10-29, accession 0000105770-26-000121.Revenue: $804.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0000105770-26-000121.Report this figure19.5%Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: $156.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-17, accession 0000105770-26-000010. Derived: 12-month figure less the 9-month figure.Revenue: $805.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000105770-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure21.0%Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: $177.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-04-23, accession 0000105770-26-000049.Revenue: $844.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-23, accession 0000105770-26-000049.Report this figure20.5%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $179.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-23, accession 0000105770-26-000099.Revenue: $872.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-23, accession 0000105770-26-000099.Report this figure30.6%Operating margin, Q3 FY2026, three months to 2026-09-30. operating income / revenueOperating income: $267.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-10-29, accession 0000105770-26-000121.Revenue: $874.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0000105770-26-000121.Report this figure
Net margin%17.4%Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: $130.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-17, accession 0000105770-26-000010. Derived: 12-month figure less the 9-month figure.Revenue: $748.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000105770-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure12.9%Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: $89.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-29, accession 0000105770-26-000121.Revenue: $698.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-23, accession 0000105770-26-000049.Report this figure17.2%Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: $131.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-29, accession 0000105770-26-000121.Revenue: $766.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-23, accession 0000105770-26-000099.Report this figure17.4%Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: $140.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-29, accession 0000105770-26-000121.Revenue: $804.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0000105770-26-000121.Report this figure16.4%Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: $132.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-17, accession 0000105770-26-000010. Derived: 12-month figure less the 9-month figure.Revenue: $805.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000105770-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure16.4%Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: $138.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-29, accession 0000105770-26-000121.Revenue: $844.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-23, accession 0000105770-26-000049.Report this figure17.7%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $154.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-29, accession 0000105770-26-000121.Revenue: $872.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-23, accession 0000105770-26-000099.Report this figure24.5%Net margin, Q3 FY2026, three months to 2026-09-30. net income / revenueNet income: $214.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-29, accession 0000105770-26-000121.Revenue: $874.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0000105770-26-000121.Report this figure
Diluted EPS$ per sharenot reported (Diluted EPS not reported)1.23Diluted EPS, Q1 FY2025, three months to 2025-03-31$1.23 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-04-23, accession 0000105770-26-000049.Report this figure1.82Diluted EPS, Q2 FY2025, three months to 2025-06-30$1.82 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-23, accession 0000105770-26-000099.Report this figure1.92Diluted EPS, Q3 FY2025, three months to 2025-09-30$1.92 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-10-29, accession 0000105770-26-000121.Report this figurenot reported (Diluted EPS not reported)1.92Diluted EPS, Q1 FY2026, three months to 2026-03-31$1.92 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-04-23, accession 0000105770-26-000049.Report this figure2.15Diluted EPS, Q2 FY2026, three months to 2026-06-30$2.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-23, accession 0000105770-26-000099.Report this figure3.02Diluted EPS, Q3 FY2026, three months to 2026-09-30$3.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-10-29, accession 0000105770-26-000121.Report this figure
Free cash flow$m85.2Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $190.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-17, accession 0000105770-26-000010. Derived: 12-month figure less the 9-month figure.Capital expenditure: $104.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-17, accession 0000105770-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure58.1Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: $129.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-04-23, accession 0000105770-26-000049.Capital expenditure: $71.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-04-23, accession 0000105770-26-000049.Report this figure102Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: $177.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-23, accession 0000105770-26-000099. Derived: 6-month figure less the 3-month figure.Capital expenditure: $75.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-23, accession 0000105770-26-000099. Derived: 6-month figure less the 3-month figure.Report this figure134Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: $197.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-10-29, accession 0000105770-26-000121. Derived: 9-month figure less the 6-month figure.Capital expenditure: $63.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-10-29, accession 0000105770-26-000121. Derived: 9-month figure less the 6-month figure.Report this figure175Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $251.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-17, accession 0000105770-26-000010. Derived: 12-month figure less the 9-month figure.Capital expenditure: $76.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-17, accession 0000105770-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure47.2Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: $89.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-04-23, accession 0000105770-26-000049.Capital expenditure: $42.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-04-23, accession 0000105770-26-000049.Report this figure80.8Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $124.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-23, accession 0000105770-26-000099. Derived: 6-month figure less the 3-month figure.Capital expenditure: $43.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-23, accession 0000105770-26-000099. Derived: 6-month figure less the 3-month figure.Report this figure150Free cash flow, Q3 FY2026, three months to 2026-09-30. operating cash flow − capital expenditureOperating cash flow: $189.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-10-29, accession 0000105770-26-000121. Derived: 9-month figure less the 6-month figure.Capital expenditure: $39.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-10-29, accession 0000105770-26-000121. Derived: 9-month figure less the 6-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$3.07bnGross margin 35.9%
Diluted EPS$6.79, FY2025
Free cash flow$468.9m, FY2025
West Pharmaceutical Services Inc, key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m2,832Revenue, FY2021, twelve months to 2021-12-31$2.83bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-20, accession 0000105770-24-000015.Report this figure2,887Revenue, FY2022, twelve months to 2022-12-31$2.89bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-18, accession 0000105770-25-000013.Report this figure2,950Revenue, FY2023, twelve months to 2023-12-31$2.95bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000105770-26-000010.Report this figure2,893Revenue, FY2024, twelve months to 2024-12-31$2.89bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000105770-26-000010.Report this figure3,074Revenue, FY2025, twelve months to 2025-12-31$3.07bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000105770-26-000010.Report this figure
Gross margin%41.5%Gross margin, FY2021, twelve months to 2021-12-31. gross profit / revenueGross profit: $1.18bn. XBRL concept us-gaap:GrossProfit. 10-K filed 2024-02-20, accession 0000105770-24-000015.Revenue: $2.83bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-20, accession 0000105770-24-000015.Report this figure39.4%Gross margin, FY2022, twelve months to 2022-12-31. gross profit / revenueGross profit: $1.14bn. XBRL concept us-gaap:GrossProfit. 10-K filed 2025-02-18, accession 0000105770-25-000013.Revenue: $2.89bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-18, accession 0000105770-25-000013.Report this figure38.3%Gross margin, FY2023, twelve months to 2023-12-31. gross profit / revenueGross profit: $1.13bn. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-17, accession 0000105770-26-000010.Revenue: $2.95bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000105770-26-000010.Report this figure34.5%Gross margin, FY2024, twelve months to 2024-12-31. gross profit / revenueGross profit: $998.5m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-17, accession 0000105770-26-000010.Revenue: $2.89bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000105770-26-000010.Report this figure35.9%Gross margin, FY2025, twelve months to 2025-12-31. gross profit / revenueGross profit: $1.10bn. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-17, accession 0000105770-26-000010.Revenue: $3.07bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000105770-26-000010.Report this figure
Operating margin%26.6%Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: $752.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-02-20, accession 0000105770-24-000015.Revenue: $2.83bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-20, accession 0000105770-24-000015.Report this figure25.4%Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: $734.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-18, accession 0000105770-25-000013.Revenue: $2.89bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-18, accession 0000105770-25-000013.Report this figure22.9%Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: $676.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-17, accession 0000105770-26-000010.Revenue: $2.95bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000105770-26-000010.Report this figure19.7%Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: $569.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-17, accession 0000105770-26-000010.Revenue: $2.89bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000105770-26-000010.Report this figure19.0%Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: $584.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-17, accession 0000105770-26-000010.Revenue: $3.07bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000105770-26-000010.Report this figure
Net margin%23.4%Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: $661.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-02-20, accession 0000105770-24-000015.Revenue: $2.83bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-20, accession 0000105770-24-000015.Report this figure20.3%Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: $585.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-18, accession 0000105770-25-000013.Revenue: $2.89bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-18, accession 0000105770-25-000013.Report this figure20.1%Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: $593.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-17, accession 0000105770-26-000010.Revenue: $2.95bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000105770-26-000010.Report this figure17.0%Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: $492.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-17, accession 0000105770-26-000010.Revenue: $2.89bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000105770-26-000010.Report this figure16.1%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: $493.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-17, accession 0000105770-26-000010.Revenue: $3.07bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000105770-26-000010.Report this figure
Diluted EPS$ per share8.67Diluted EPS, FY2021, twelve months to 2021-12-31$8.67 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-20, accession 0000105770-24-000015.Report this figure7.73Diluted EPS, FY2022, twelve months to 2022-12-31$7.73 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-02-18, accession 0000105770-25-000013.Report this figure7.88Diluted EPS, FY2023, twelve months to 2023-12-31$7.88 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-17, accession 0000105770-26-000010.Report this figure6.69Diluted EPS, FY2024, twelve months to 2024-12-31$6.69 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-17, accession 0000105770-26-000010.Report this figure6.79Diluted EPS, FY2025, twelve months to 2025-12-31$6.79 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-17, accession 0000105770-26-000010.Report this figure
Free cash flow$m331Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: $584.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-20, accession 0000105770-24-000015.Capital expenditure: $253.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-02-20, accession 0000105770-24-000015.Report this figure439Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: $724.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-18, accession 0000105770-25-000013.Capital expenditure: $284.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-18, accession 0000105770-25-000013.Report this figure415Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: $776.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-17, accession 0000105770-26-000010.Capital expenditure: $362.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-17, accession 0000105770-26-000010.Report this figure276Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $653.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-17, accession 0000105770-26-000010.Capital expenditure: $377.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-17, accession 0000105770-26-000010.Report this figure469Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $754.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-17, accession 0000105770-26-000010.Capital expenditure: $285.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-17, accession 0000105770-26-000010.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding West Pharmaceutical Services Inc
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BlackRock, Inc.2026-06-30$2.39bn6,651,784Reduced−184,930
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$1.66bn4,613,134Reduced−70,152
VANGUARD PORTFOLIO MANAGEMENT LLC2026-06-30$1.44bn4,015,766Reduced−78,243
FMR LLC2026-06-30$1.28bn3,574,816Added+2,325,068
STATE STREET CORP2026-06-30$1.20bn3,348,698Added+54,920
Artisan Partners Limited Partnership2026-06-30$865.8m2,411,792Reduced−246,101
Bank of New York Mellon Corp2026-06-30$733.7m2,043,823Reduced−422,035
GENERATION INVESTMENT MANAGEMENT LLP2026-06-30$728.2m2,028,322Reduced−215,654
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$680.6m1,903,279Reduced−9,176
MORGAN STANLEY2026-06-30$568.1m1,582,546Added+124,264

Recent filings

All 1,721 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

West Pharmaceutical Services Inc, recent filings
FiledFormWhat it isAccession number
2026-10-2916:17 ET10-QQuarterly reportPeriod 2026-09-300000105770-26-000121
2026-10-2907:06 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0000105770-26-000118
2026-10-2617:14 ET8-K1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits0000105770-26-000114
2026-07-2316:15 ET10-QQuarterly reportPeriod 2026-06-300000105770-26-000099
2026-07-2307:14 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0000105770-26-000097
2026-07-1416:29 ET8-K1.01 Entry into a material agreement; 9.01 Financial statements and exhibits0000105770-26-000093
2026-06-0116:32 ET8-K5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0000105770-26-000080
2026-05-2016:04 ET8-K/A1.05 Material cybersecurity incident; 9.01 Financial statements and exhibits0000105770-26-000077
2026-05-1117:06 ET8-K1.05 Material cybersecurity incident; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0000105770-26-000068
2026-05-0516:49 ET8-K5.07 Shareholder vote results; 9.01 Financial statements and exhibits0000105770-26-000056

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 17, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, has been scored from the reported figures.See the target

About the filer

CIK
105770
Tickers
WST
Exchange
NYSE
SIC code
3841 Surgical & Medical Instruments & Apparatus
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
PA
Filer category
Large accelerated filer
Former names
WEST CO INC (to 1999-02-11)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 18:13 ET. Listed shows no prices and gives no investment advice.